JP2018515557A - うつ病を治療するための方法及びキット - Google Patents

うつ病を治療するための方法及びキット Download PDF

Info

Publication number
JP2018515557A
JP2018515557A JP2017560314A JP2017560314A JP2018515557A JP 2018515557 A JP2018515557 A JP 2018515557A JP 2017560314 A JP2017560314 A JP 2017560314A JP 2017560314 A JP2017560314 A JP 2017560314A JP 2018515557 A JP2018515557 A JP 2018515557A
Authority
JP
Japan
Prior art keywords
esketamine
during
patient
administered
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017560314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515557A5 (https=
Inventor
シン，ジャスカラン
カエルス，イヴォ
ダリー，エラ
シー． ドレヴェツ，ワイン
シー． ドレヴェツ，ワイン
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2018515557A publication Critical patent/JP2018515557A/ja
Publication of JP2018515557A5 publication Critical patent/JP2018515557A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
JP2017560314A 2015-05-20 2016-05-20 うつ病を治療するための方法及びキット Pending JP2018515557A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562164026P 2015-05-20 2015-05-20
US62/164,026 2015-05-20
PCT/US2016/033404 WO2016187491A1 (en) 2015-05-20 2016-05-20 Methods and kits for treating depression

Publications (2)

Publication Number Publication Date
JP2018515557A true JP2018515557A (ja) 2018-06-14
JP2018515557A5 JP2018515557A5 (https=) 2019-06-13

Family

ID=57320901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017560314A Pending JP2018515557A (ja) 2015-05-20 2016-05-20 うつ病を治療するための方法及びキット

Country Status (20)

Country Link
US (1) US20160338977A1 (https=)
EP (1) EP3297618A4 (https=)
JP (1) JP2018515557A (https=)
KR (1) KR20180008634A (https=)
CN (1) CN107735081A (https=)
AU (3) AU2016263598A1 (https=)
CA (1) CA2986477A1 (https=)
CL (1) CL2017002904A1 (https=)
CO (1) CO2017011564A2 (https=)
DO (1) DOP2017000268A (https=)
EA (1) EA201792545A1 (https=)
EC (1) ECSP17077930A (https=)
GT (1) GT201700246A (https=)
HK (1) HK1252937A1 (https=)
IL (1) IL255463A (https=)
MA (1) MA42135A (https=)
MX (1) MX2017014797A (https=)
PE (1) PE20180260A1 (https=)
PH (1) PH12017502103A1 (https=)
WO (1) WO2016187491A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021529732A (ja) * 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
JP2022502429A (ja) * 2018-09-28 2022-01-11 セロン ファーマ エス.アー.Celon Pharma S.A. 肺投与によるうつ病の処置方法における使用のためのケタミン組成物
JP2022504036A (ja) * 2018-10-05 2022-01-13 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害を治療するためのエスケタミンの投与計画
JP2022524008A (ja) * 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
US12076300B2 (en) 2019-12-30 2024-09-03 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
CN106714789A (zh) 2014-08-13 2017-05-24 詹森药业有限公司 用于治疗抑郁症的方法
CN107208133A (zh) 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
WO2020070547A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070706A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
US20220304950A1 (en) * 2019-08-28 2022-09-29 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of patients with major depressive disorder, including suicidality
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021242504A1 (en) * 2020-05-28 2021-12-02 Janssen Pharmaceuticals, Inc. Methods for treating depression
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20130236573A1 (en) * 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
US20140221473A1 (en) * 2011-06-30 2014-08-07 Jahanshah Amin Compositions, Methods of Use, and Methods of Treatment
WO2014169272A1 (en) * 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107208133A (zh) * 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20140221473A1 (en) * 2011-06-30 2014-08-07 Jahanshah Amin Compositions, Methods of Use, and Methods of Treatment
US20130236573A1 (en) * 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
WO2014169272A1 (en) * 2013-04-12 2014-10-16 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"うつ病に対する薬の使い時，止め時−薬物療法の現状 Starting and stopping pharmacotherapy of depr", 医学のあゆみ 第２１９巻 第１３号, vol. 219, no. 13, JPN6020010730, 2006, pages 949 - 953, ISSN: 0004402024 *
岡山医学会雑誌, vol. 119, JPN6020010733, 2008, pages 315 - 317, ISSN: 0004402025 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021529732A (ja) * 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
US12036189B2 (en) 2018-06-27 2024-07-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP2022502429A (ja) * 2018-09-28 2022-01-11 セロン ファーマ エス.アー.Celon Pharma S.A. 肺投与によるうつ病の処置方法における使用のためのケタミン組成物
JP7444864B2 (ja) 2018-09-28 2024-03-06 セロン ファーマ エス．アー． 肺投与によるうつ病の処置方法における使用のためのケタミン組成物
US12280022B2 (en) 2018-10-05 2025-04-22 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP2022504036A (ja) * 2018-10-05 2022-01-13 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害を治療するためのエスケタミンの投与計画
US11957645B2 (en) 2018-10-05 2024-04-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
US12514831B2 (en) 2018-10-05 2026-01-06 Clexio Biosciences Ltd. Method of treating major depressive disorder
US12336970B2 (en) 2018-10-05 2025-06-24 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP2022524008A (ja) * 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
JP2025003983A (ja) * 2019-03-05 2025-01-14 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
US12268658B2 (en) 2019-12-30 2025-04-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
US12076300B2 (en) 2019-12-30 2024-09-03 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Also Published As

Publication number Publication date
US20160338977A1 (en) 2016-11-24
AU2016263598A8 (en) 2017-11-30
AU2023237026A1 (en) 2023-10-12
EP3297618A1 (en) 2018-03-28
PE20180260A1 (es) 2018-02-05
IL255463A (en) 2018-01-31
PH12017502103A1 (en) 2018-05-07
AU2016263598A1 (en) 2017-11-23
HK1252937A1 (zh) 2019-06-06
CL2017002904A1 (es) 2018-04-20
MX2017014797A (es) 2018-02-15
EP3297618A4 (en) 2019-01-23
AU2021215155A1 (en) 2021-09-02
MA42135A (fr) 2018-03-28
GT201700246A (es) 2019-07-29
CN107735081A (zh) 2018-02-23
WO2016187491A1 (en) 2016-11-24
CO2017011564A2 (es) 2018-04-19
DOP2017000268A (es) 2018-04-15
CA2986477A1 (en) 2016-11-24
EA201792545A1 (ru) 2018-05-31
KR20180008634A (ko) 2018-01-24
ECSP17077930A (es) 2018-02-28

Similar Documents

Publication Publication Date Title
JP2018515557A (ja) うつ病を治療するための方法及びキット
Suppes et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder
JP2021054829A (ja) Ｖａｌ６６Ｍｅｔ（ＳＮＰ ｒｓ６２６５）遺伝子型特異的投薬レジメン及びうつ病の治療のための方法
CA3086478A1 (en) Esketamine for the treatment of depression
US20130236573A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
US20240325296A1 (en) Esketamine for the treatment of depression
US20200009081A1 (en) Delivery Of Esketamine For The Treatment Of Depression
JP7273037B2 (ja) ３－メチルメトカチノンの使用
CN103298462A (zh) 降低暴食或强迫进食的方法
Bourke Fibromyalgia and chronic fatigue syndrome: management issues
Haghparast et al. Sedatives and hypnotics
Fineberg et al. Pharmacotherapy for obsessive—compulsive disorder
JP2019514978A (ja) イブジラストを使用したアルコール依存症並びにうつ病及び／又は不快な気分の治療
Fujioka Sustained-release naltrexone/bupropion-a novel pharmacologic approach to obesity and food craving
JP7840873B2 (ja) うつ病の治療方法
Sanacora Ketamine-Induced Optimism: New Hope for the Development of Rapid-Acting Antidepressants.
Williams Pharmacological management of binge eating disorder
Khouzam Treatment Resistant Depression: Review of its Therapeutic Interventions
RU2788450C2 (ru) Способы проведения терапии потери веса у пациентов с доминирующей депрессией
Ketter et al. Overview of pharmacotherapy for Bipolar Disorder
AU2013203567A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
Rizek et al. Management of Advanced Parkinson’s Disease
Frieden White House announces health IT grants
Bradford et al. Therapy: Recent Progress in Clinical Applications and Research in Fibromyalgia--Part 3
Naidoo et al. P. 4. c. 003 Mother's little helper: prescribing practice of anxiolytics and hypnotics in a community mental health team

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200923

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210706